ABSTRACT
1
Immunohistochemical (IHC) staining for thyroid transcription factor 1 (TTF-1) is one of the most reliable tests for distinguishing primary AC of the lung from SCC and metastatic AC. TTF-1 is highly specific for lung and thyroid ACs and high-grade neuroendocrine carcinomas. 2, 3 However, occasional positivity for TTF-1 has been shown in other extrapulmonary tumors, such as primary tumors from colorectal, [4] [5] [6] [7] [8] gastric, 9 cervical, endometrial and ovarian, [10] [11] [12] [13] breast, 14, 15 and prostatic AC, 9, 16 as well as salivary gland tumors, 9 urothelial carcinomas, 9 renal cell carcinomas, 7 cholangiocarcinomas, 17 and primary brain tumors. [18] [19] [20] Also, some pulmonary metastases from colorectal, 4, [6] [7] [8] renal, prostatic, ovarian, endometrial, and salivary gland carcinomas 7 have been reported as TTF-1 positive.
TTF-1 has been rather comprehensively investigated in primary tumors of nonpulmonary origin, but few studies have investigated the rate of TTF-1 expression in metastases to the lungs, which is more relevant for the clinical situation. 4, 7 Also, there is no comprehensive comparison with the newly introduced TTF-1 clone SP141. Evidently, different TTF-1 clones are directed against different epitopes and thus possess different affinities, leading to different IHC staining patterns. Clone SPT24 has been shown to stain pulmonary SCC rather frequently and sometimes also metastases to the lung, although limited data exist for the latter. 4, 5, 9, 21 Clone 8G7G3/1 generally shows a weaker staining intensity and has been reported to be positive in pulmonary metastases less frequently compared with SPT24 in two studies 4, 5 but to about the same extent as SPT24 in one study. 6 We have previously investigated TTF-1 clones 8G7G3/1 and SPT24 in more than 650 cases of pulmonary non-small cell carcinomas, all included in the present study. 22 Now we have added TTF-1 clone SP141 and investigated all three clones in a new cohort of 428 epithelial metastases to the lungs as well as their primary tumors when available. The aim of the present study was to compare the staining properties of the three TTF-1 clones 8G7G3/1, SPT24, and SP141 in lung cancer and pulmonary metastases from epithelial tumors based on unselected material.
Materials and Methods

Study Population-Primary Lung Cancers
The present study included 665 resected primary lung cancers from 657 individuals (eight cases with two synchronous primary lung cancers each) originally included in three independent unselective cohorts with tumor tissue available and evaluable on tissue microarrays (TMAs).
The first cohort consisted of 355 tumors from 351 patients who were surgically treated at the Uppsala University Hospital, Uppsala, Sweden, from 2006 to 2010. 22, 23 The second cohort consisted of 207 tumors from 205 patients who were prospectively included in the Southern Swedish Lung Cancer Study and surgically treated at the Skåne University Hospital, Lund, Sweden, from 2005 to 2011. [22] [23] [24] One case diagnosed and reported as primary lung SCC in our previous publications on this cohort has been proven with further IHC staining to be a pulmonary metastasis of the patient's previous urothelial carcinoma and hence excluded. The third cohort consisted of 115 lung cancers from 113 patients included in the population-based prospective Malmö Diet and Cancer Study 25, 26 and surgically treated at the Skåne University Hospital, Lund, Sweden, from 1996 to 2010. 22 Twelve of these cases were also included in the Southern Swedish Lung Cancer Study, and each of these cases was only included once in the present study.
All cases were previously updated in adherence with the fourth edition of the World Health Organization (WHO) classification on lung cancer from 2015, 1 and the results of IHC staining for TTF-1 clones 8G7G3/1 and SPT24 have been published elsewhere. 22 Note that in comparison with the previous publication, the present study included any small cell lung carcinomas (SCLCs) and carcinoid tumors in the cohorts.
Study Population-Pulmonary Metastases
The pulmonary metastases cohort was a retrospective consecutive study from the Skåne University Hospital in Lund covering the years 2000 to 2014. All cases with lung resection (wedge resection, lobectomy, etc) of an epithelial malignant tumor consistent with a metastasis were included. All cases had a previously known cancer at another site or a cancer was detected at another site (and subsequently pathologically examined) at the time of investigation of the tumor in the lung.
The cohort included 351 patients with 440 resected pulmonary metastases. There were 13 cases with no tumor tissue on the TMA slides in the present study (mainly due to very small tumors), while 428 pulmonary metastases from 344 patients were available for assessment (60 cases had each two and 12 cases had each three resected metastases to the lungs from the same tumor). An overview of the included cases is seen in ❚Table 1❚. In total, 62 (14%) of the 428 pulmonary metastases were synchronous (here defined as detectable by radiologic or peroperative surgical investigation at the time of detection or surgical treatment of the primary tumor) while 366 (86%) were metachronous.
In the clinical setting, the diagnosis of metastatic tumor to the lung was based on morphology, comparison with the primary tumor, and other features such as pattern of spread (eg, multiple small tumors in the lungs, metastases to other sites besides the lungs). In rare cases, molecular analysis was used for a diagnostic purpose (comparison of a mutational profile in primary tumor and lung metastasis). 27 IHC stains had also been used in the clinical setting for many of the cases. However, cases with a lung tumor in which the pathologist could not completely exclude metastasis based on the IHC profile (such as an AC that was positive for CK7 but negative for TTF-1 and napsin A) but with no clinical or radiologic evidence of a nonpulmonary primary tumor were not included in the present study. Typically, the patients had been investigated with computed tomography scan and had been discussed at a multidisciplinary disease-specific tumor board. All cases were handled as metastases to the lungs in the clinical setting.
In the present study, data for the years after removal of the tumor in the lung were also available, including subsequent biopsies and surgical specimens. All slides from primary tumors and metastases were reviewed by a PhD student (H.V.) and a pathologist (H.B.). During the years of investigation, reevaluation including extensive IHC staining proved distinct different morphology and IHC profiles between the tumor in the lung and the nonthoracic tumor in four cases that were originally diagnosed as metastases to the lungs (three cases of colorectal carcinoma and one endometrial carcinoma). Thus, these cases were excluded as misdiagnosed primary lung cancers and separate nonthoracic tumors.
The routine handling of resected lung specimens during the included years was fixation in 10% neutral aqueous formalin (corresponding to 4% formaldehyde) typically for 48 hours before gross sectioning and further processing before paraffin embedding. In the present study, well-fixed and not previously snap-frozen tissue blocks were selected except in six pulmonary metastases in which only previously snap-frozen tissue was available.
TMAs were constructed with two cores each 1 mm in diameter from each tumor. In addition to the metastasis, cores were taken from the primary tumor when available. Reasons for not including the primary tumor included nonsurgical treatment (eg, radiation therapy of prostatic cancer, transurethral resection of bladder cancer, or combined chemotherapy and radiation therapy of advanced disease), neoadjuvant treatment with limited or no viable tumor in the surgical specimen (eg, rectal cancer), primary tumor surgically treated outside the Region Skåne county, and tumor blocks missing due to inclusion in other studies or unknown reason. Also, in a few cases, there was no tumor on the TMA slides. If several metastases to the lungs had been surgically treated, cores were taken from each metastasis. For cases with colorectal cancer, cores were also taken from any surgically treated liver metastases that were available in cases in which cores were also taken from the primary tumor in the colon/rectum.
Immunohistochemistry
The 4-μm-thick tissue sections from the TMAs were automatically pretreated (Ventana Cell Conditioning 1, EDTA, pH 8; Ventana Medical Systems, Tucson, AZ) and stained with the TTF-1 monoclonal antibodies 8G7G3/1 (ready to use, with amplification; Ventana Medical Systems), SP141 (ready to use; Ventana Medical Systems), and SPT24 (1:50; Leica Biosystems, Nussloch, Germany) on a Ventana BenchMark Ultra automated slide stainer using the Ventana ultraView Universal DAB Detection Kit (Ventana Medical Systems).
For clone SPT24, the primary lung cancers were instead pretreated (Dako Target Retrieval Solution, high pH, EDTA, pH 9; Dako, Glostrup, Denmark) and stained (1:100; Leica Biosystems) on a Dako Autostainer Link 48, PT Link, with EnVision DAB Detection System (Dako). Previous comparisons of the SPT24 staining with the two different protocols on a Ventana and Dako stainer, respectively, on a subset of the included cases revealed no significant differences (own unpublished data).
Control tissue was used on each slide. Areas with normal lung tissue with terminal bronchioles were present on all slides in addition to thyroid tissue as external positive control, and for most individual cases of pulmonary metastasis, type II pneumocytes were present on the TMA slides.
The TTF-1-stained TMA slides for the pulmonary metastasis cohort were reviewed together by a PhD student (H.V.) and a pathologist (H.B.). Disagreements between the two reviewers were resolved by discussion and consensus. The slides for the primary lung cancer cohorts were reviewed by a pathologist (H.B.). The fraction of IHC-positive viable tumor cells was divided into five categories: less than 1%, 1% to 9%, 10% to 24%, 25% to 49%, and 50% or more. Special care was taken to not interpret trapped alveolar or bronchiolar epithelium as positive tumor cells. In adherence to the fourth edition of the WHO classification (guidelines for diagnosis of large cell carcinoma [LCC]) 1 and previous data, 
Statistical Analysis
The frequency of TTF-1-positive cases was compared between the three clones using a paired nonparametric test, Wilcoxon's test. A P value of less than .05 was considered statistically significant. Receiver operating characteristics (ROC) analysis was used to identify the best cutoff for the TTF-1 clones to separate nonsquamous lung cancers and lung AC from other tumors. All analyses were performed with MedCalc Statistical Software version 14.12.0 (MedCalc Software, Ostend, Belgium).
Results
TTF-1 Expression in Primary Lung Cancers
The lung cancer cohorts included 657 patients, 303 men (46%) and 354 women (54%), with a median age of 68 years (range, 43-84 years) at the time of surgery. In total, 665 primary lung cancers were resected (eight patients each with two synchronous tumors), of which there were 415 ACs, 193 SCCs, 12 LCCs, eight adenosquamous carcinomas, six sarcomatoid carcinomas (SCs), 21 large cell neuroendocrine carcinomas (LCNECs; six of which were combined LCNEC with an AC component), three SCLCs, and seven carcinoid tumors. The AC and SCC components were evaluated separately for adenosquamous carcinoma and combined LCNEC and were grouped with the "pure" AC and SCC cases, respectively. ❚Table 2❚ shows the results of the IHC staining with the different TTF-1 antibody clones.
Using the same cutoff of 1% for a positive test for all TTF-1 clones, a higher number of positive cases were seen with clones SPT24 and SP141 than with clone 8G7G3/1 for all histologic subtypes except SCLC and SC, in which the three clones showed the same result. Of the 429 AC cases (including the AC component of the 14 mixed tumors), 380 (89%) exhibited positivity for the TTF-1 clone 8G7G3/1 in at least 1% of the cells. Correspondingly, 397 (93%) cases were positive with clone SPT24, and 388 (93% of 419 evaluable) were positive with clone SP141. No SCC case was positive for TTF-1 clone 8G7G3/1, while 12 (6% of 201, including the SCC component of adenosquamous carcinomas) and 16 (8% of 197 evaluable) were positive with clones SPT24 and SP141, respectively. In half of these, less than 10% of the tumor cells were positive.
A comparison of staining with the three different TTF-1 clones in a typical AC case and adjacent benign respiratory bronchiole is seen in ❚Image 1❚, while ❚Image 2❚ shows a case of SCC with partial TTF-1 positivity with clones SPT24 and SP141.
TTF-1 Expression in Pulmonary Metastases
The cohort of cases with resected metastases to the lungs comprised 344 patients, 179 men (52%) and 165 women (48%), with a median age of 66 years (range, 37-87 years) at time of surgery of the metastasis to the lung (time of the first metastasis if several were surgically removed). In total, 428 metastases to the lungs were available for analysis (72 patients with two or more resected metastases). Most were metastases from colorectal carcinomas, 280 (66%) cases, in decreasing order followed by 42 renal cell carcinomas, 27 breast cancers, 20 gynecologic cancers, 19 other gastrointestinal cancers, 11 prostatic cancers, nine head and neck cancers, eight urothelial carcinomas, five thymomas, four skin cancers, and three thyroid cancers. Of these, 30 (7%) metastases expressed TTF-1 with any clone. See Table 1 for details.
Colorectal Carcinomas
Among the 280 resected pulmonary metastases from colorectal carcinoma, five (2%) tumors from five different individuals were positive with TTF-1 clone 8G7G3/1. Among the 166 evaluated primary colorectal carcinomas from these patients, three (2%), seven (4%), and seven (4%) were positive with TTF-1 clone 8G7G3/1, clone SPT24, and clone SP141, respectively. Three cases were positive with all three clones, three were positive with clones SPT24 and SP141 only, and one case was positive with clone SPT24 only and one with clone SP141 only. From cases with both pulmonary metastasis and primary tumor available, 57 liver metastases from 48 patients were available for evaluation. Seven (12%) liver metastases from six individuals were positive for TTF-1, five tumors for all three clones and two for SPT24 and SP141 only.
In one of the cases with TTF-1-positive primary rectal AC (all three clones >25%), the metastases to the lung and liver were both negative for TTF-1 (all clones). Whole tumor sections from the metastases were negative as well. Of the 61 patients with more than one resected pulmonary metastasis of colorectal cancer, seven had a TTF-1-positive pulmonary metastasis (clone SPT24 and/ or SP141), all of them with two different metastases to the lungs. In two cases, both pulmonary metastases were TTF-1 positive, but in the other five cases, only one of the metastases was TTF-1 positive.
Other Tumors
One pulmonary metastasis of urothelial carcinoma was positive for TTF-1, and in that case TTF-1 was positive with all three clones (10%-25% for 8G7G3/1 and >50% for SPT24 and SP141). The primary tumor was not available for analysis. See Table 1 for details.
All included pulmonary metastases from the gastrointestinal tract other than colorectal cancer were negative with TTF-1 clone 8G7G3/1. One metastasis of small bowel AC was positive with clones SPT24 and SP141 in less than 10% of the tumor cells. The primary tumor was TTF-1 negative. One metastasis of pancreatic AC was positive with the SPT24 clone in less than 10% of the tumor cell but negative with clones SP141 and 8G7G3/1. See ❚Image 4❚. The primary tumor was not available for staining.
All included pulmonary metastases from gynecologic cancers were negative with TTF-1 clone 8G7G3/1. One metastasis from cervical AC was positive in less than ❚Image 1❚ Immunohistochemical staining with three different thyroid transcription factor 1 antibody clones in a case of primary lung adenocarcinoma with a lepidic growth pattern (arrows) with adjacent benign respiratory bronchiole (arrowheads). A, H&E. B, Clone 8G7G3/1. C, Clone SPT24. D, Clone SP141. (×200)
10% of the cells with both clones SPT24 and SP141. The primary tumor was not available for staining. In another case of cervical AC, two of three different resected pulmonary metastases from the same patient were positive with either clone SPT24 or SP141 in less than 10% of the tumor cells. See Image 4 for one of the cases. The primary tumor was TTF-1 negative.
Two pulmonary metastases from thyroid follicular and papillary carcinomas, respectively, were positive in more than 50% of the cells for all three TTF-1 clones. A different case of pulmonary metastasis of anaplastic thyroid cancer was TTF-1 negative (a whole tumor section from the metastasis was negative as well) while the primary tumor was TTF-1 positive.
Differences Between TTF-1 Clones
Significantly more cases of pulmonary metastases were positive with TTF-1 clones SPT24 (n = 26) and SP141 (n = 27) than with clone 8G7G3/1 (n = 8) using 1% positive cells as the cutoff for a positive test for all clones (Wilcoxon's test, both P < .0001). If using 10% positive cells as a cutoff for a positive test for clones SPT24 and SP141, the number of TTF-1-positive pulmonary metastases (n = 15 and n = 16, respectively) was still significantly higher than with clone 8G7G3/1 with 1% positive cells as the cutoff (both P < .005), while the difference was not significant (n = 13 and n = 14, respectively) if using 25% positive cells as the cutoff for clones SPT24 and SP141 (both P = .06). There was no significant difference in the number of positive cases between clones SPT24 and SP141 regardless of the cutoff level (all P > .5).
To separate cases with nonsquamous lung cancer from cases with lung SCC and pulmonary metastasis, an ROC analysis identified 1% positive cells as the best cutoff for TTF-1 clone 8G7G3/1 (sensitivity of 85%, specificity of 99%, area under curve of 0.92) and for clone SPT24 (sensitivity of 90%, specificity of 94%, area under curve of 0.94). For SP141, 10% positive cells was identified as the best cutoff (sensitivity of 88%, specificity of 96%, area under curve of 0.93; cutoff of 1% resulted in a sensitivity of 89% and a specificity of 93%). If instead the ROC analysis was performed to separate lung AC from nonadenocarcinomatous lung cancer and pulmonary metastasis, 10% and 50% were instead the best cutoffs for clones SPT24 and SP141, respectively (sensitivity of 90% and 89%, specificity of 93% and 94%, and area under curve of 0.93 and 0.93, respectively), while 1% remained the optimal cutoff for clone 8G7G3/1 (sensitivity of 88%, specificity of 96%, area under curve of 0.93).
Comparison With Whole Tumor Sections
From the clinical setting, a whole tumor section (typically from another block than the one used for TMA) stained with TTF-1 clone 8G7G3/1 was available for 123 of the metastases to the lungs (in which 74 [60%] were of colorectal origin). The staining was negative in both TMA and whole tumor section in 118 of these cases and positive in both in one metastasis of colorectal cancer (both 10%-24% positive tumor cells). In one metastasis of urothelial carcinoma, the staining was positive on TMA (10%-24% of the cells) while negative on the whole tumor section (which was more than 15 years old). In another metastasis of urothelial carcinoma and in two metastases of colorectal cancer, there was focal TTF-1 positivity (1%-9% and 10%-24%, respectively) on the whole tumor section while the staining was negative on TMA.
Additional staining of a whole tumor section with clone SPT24 was performed for 18 (in which 15 [83%] were of colorectal origin) pulmonary metastases positive for any TTF-1 clone on TMA but with less than 50% positive tumor cells for all clones (block missing for one such case). In 11 of these, the score was the same on the whole tumor section as on TMA, while the score on the whole section was one step higher for five cases (eg, 10%-24% vs 1%-9%) and one or two steps lower for two cases.
Discussion
In a study by Ye et al, 7 14% of 103 pulmonary metastases of mixed origin were positive for TTF-1 clone 8G7G3/1. The use of larger tissue cores in that study could possibly contribute to the higher frequency compared with An even higher frequency of TTF-1-positive pulmonary metastases from colorectal carcinoma has been reported from very small series. [5] [6] [7] Generally, TTF-1 clone SPT24 was reported positive more often than clone 8G7G3/1 in these studies. In contrast, Matoso et al 9 found that both clones stained nonpulmonary tumors with similar intensity and distribution, with three (2.5%) of 120 primary colon carcinomas positive with both clones. Differences in staining protocols for either or both clones compared with ours may be a possible explanation, as the staining was about as strong for both clones in the study by Matoso et al. 9 Both Turner et al 28 and Bae et al 8 reported no TTF-1-positive primary colon carcinomas with clone 8G7G3/1, while in the latter, a recent study with over 1,300 cases, 5% of the cases were positive with clones SPT24 and SP141 using 5% positive tumor cells as a cutoff for a positive staining. Interestingly, right-sided colon cancers were less often TTF-1 positive than left-sided and rectal cancers in both that study and in our material. 30 included 118 primary renal cell carcinomas that were all negative for TTF-1, but rare TTF-1-positive pulmonary metastasis from renal cell carcinoma has been described. 7 Matoso et al 9 examined 98 primary urothelial bladder tumors, of which five were TTF-1 positive, while also reporting 110 pancreatic ACs, all negative with TTF-1 clone SPT24. Several primary gastric ACs and cholangiocarcinomas have also been reported as positive for TTF-1 clone SPT24.
17,31 TTF-1-positive primary cervical, endometrial, and ovarian ACs have been described in several studies. [10] [11] [12] 32 In particular, the study by Zhang et al 11 showed rather frequent TTF-1 positivity, with variation depending on clone, detection system, histologic type, and whether TMAs or whole sections were used.
The main strengths of our study are that it is a large cohort of surgically resected pulmonary metastases, to our knowledge the largest yet, and that we compared ❚Image 4❚ Two cases with pulmonary metastasis of adenocarcinoma from pancreas and cervix, respectively, with focal positivity for thyroid transcription factor 1 (TTF-1) clone SPT24 (the cervical carcinoma was also focally positive with clone SP141, and both were negative with clone 8G7G3/1, not shown). three different TTF-1 clones, including the new clone SP141. Also, the use of pulmonary metastases instead of primary tumors from other sites more resembles the clinical situation of diagnostics of pulmonary tumors where there is a need to differentiate between primary lung cancer and pulmonary metastasis, as well as between different histologic types of lung cancer.
The main limitation of our study is the use of TMAs and not whole tumor sections, which may lead to focal TTF-1 positivity being missed, as seen in a limited number of cases in our comparison with whole tumor sections for a subset of the pulmonary metastases. However, consecutive TMA sections are often ideal for method comparisons, since the same areas from a large number of cases can be assessed. Moreover, the cohort of pulmonary metastases is not perfectly representative of all patients with pulmonary metastases. All cases where the diagnosis could be established by biopsy or cytology and in which surgery was not a method of treatment would not be included in the study. While small specimens are clinically the most relevant samples for pulmonary tumors, this would lead to inclusion of cases relying on the IHC markers we wanted to evaluate for diagnosis. Also, cases with obvious metastatic features, such as multiple small nodules in the lungs, are not always examined histopathologically. On the other hand, these cases are not relevant for TTF-1 staining in the clinical setting, as the diagnosis is obvious. The exclusion of nonepithelial tumors is probably of limited or no importance for the results of our study.
During the covered years of the present study, we identified three cases erroneously diagnosed as pulmonary metastasis of colorectal cancer on resected specimens. Comparisons with the primary tumor, including comprehensive IHC panels, were performed, and the pulmonary tumor proved to be separate primary lung cancers (and the cases consequently excluded from the study). In these cases, routine staining with TTF-1 would have been beneficial in the clinical setting (for all cases, the colorectal and pulmonary tumors had dissimilar expression of napsin A, CDX2, CK7, and CK20 as well). In contrast with the recommendations in the current WHO classification of tumors in the lungs, 1 in our opinion, routine staining with TTF-1 should be considered also on biopsy/cytology with AC with obvious glands or mucin inclusions encountered in the lung since a positive test strengthens pulmonary origin. However, it is important to keep in mind that a pulmonary metastasis from colorectal carcinoma can be TTF-1 positive also with clone 8G7G3/1, and not all primary lung ACs are TTF-1 positive.
Due to the lower specificity of TTF-1 clone SPT24 for lung AC, it has been argued that clone 8G7G3/1 may be of better use in clinical practice. 21 TTF-1-positive pulmonary SCC is problematic since these cases may not benefit from costly EGFR, ALK, and ROS1 testing and are at least partly treated differently than AC. Our and other studies show that there are also more problems with TTF-1-positive pulmonary metastases if clone SPT24 or SP141 is used. For the latter two, a cutoff of 10% positive tumor cells for a positive test seems to be more useful than 1% and may help overcome the issue of low specificity.
Metastases of lung cancer outside the lungs are less often TTF-1 positive, 9, 23 and there may be more TTF-1-positive nonpulmonary tumors outside the lungs, something not addressed in the present study. Also, future studies with more cases of pulmonary metastases from tumors other than colorectal carcinoma are warranted.
In conclusion, based on assessment of both primary lung cancers and epithelial pulmonary metastases, TTF-1 expression differs between clones, with the 8G7G3/1 clone being more specific but less sensitive for lung AC compared with clones SPT24 and SP141. A significant number of colorectal carcinomas are TTF-1 positive, especially with clones SPT24 and SP141, which should be kept in mind when differentiating between primary lung cancer and pulmonary metastases.
